New drug combo may make stem cell transplants safer for tough blood cancers
NCT ID NCT07044544
First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 30 times
Summary
This early-stage study tests whether adding two drugs, decitabine and venetoclax, to a standard stem cell transplant can make the treatment safer for people with high-risk blood cancers like leukemia. About 20 adults aged 18-75 with a matching donor will receive the new drug combination before their transplant. The main goal is to find the safest dose and check for serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
RECRUITINGBirmingham, Alabama, 35294, United States
Contact
Contact
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.